PROSPECTS AND OPPORTUNITIES
Inflationary pressures expected to ease, unit price growth expected to slow
Analgesics in New Zealand is expected to maintain slow and stable retail current value growth in the forecast period. Within systemic analgesics, although rising from a low base, diclofenac is set to see the strongest rate of retail current value growth, while ibuprofen will continue to account for the highest sales.
Impact on analgesics of pseudoephedrine regulatory changes remains uncertain
While the government has relaxed restrictions on the sale and supply of OTC products containing pseudoephedrine in 2024, the impact of this change remains uncertain. Internationally, leading analgesics brands such as Panadol offer variants containing pseudoephedrine; however, against a backdrop of heightened levels of retail crime over the review period, seeing vape stores, convenience stores, and jewellery stores targeted by ram raids, pharmacies have expressed a reluctance to stock and sell products containing pseudoephedrine, given the association these products have with organised crime, as it is used as an ingredient in the manufacture of methamphetamine.
Strong brand awareness to drive continued dominance for the incumbent leaders, but the competition is increasing
Product performance and efficacy are major attributes affecting decision-making within analgesics, as consumers want to purchase products which they know will treat their need. Thus, the brand equity and trust enjoyed by popular brands such as Panadol (Haleon New Zealand ULC) and Nurofen (Reckitt Benckiser New Zealand Ltd) will ensure these brands continue to lead the category over the forecast period.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Analgesics industry in New Zealand with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in New Zealand, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Analgesics in New Zealand report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Analgesics in New Zealand?
- Which are the leading brands in Analgesics in New Zealand?
- How are products distributed in Analgesics in New Zealand?
- How has the regulatory and operating environment for Analgesics changed in New Zealand?
- How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
- How significant are wider health concerns and consumer awareness in determining sales?
- Where is future growth expected to be most dynamic?
Analgesics in New Zealand - Category analysis
KEY DATA FINDINGS
Cold and flu incidence rates up on 2023, driving growth in demand for analgesics
Supermarkets and pharmacies remain the dominant distribution channels
Inflationary pressures drive unit price growth, cost of living pressures drive growth for private label
Inflationary pressures expected to ease, unit price growth expected to slow
Impact on analgesics of pseudoephedrine regulatory changes remains uncertain
Strong brand awareness to drive continued dominance for the incumbent leaders, but the competition is increasing
Consumer Health in New Zealand - Industry Overview
Consumer health in 2024: The big picture
2024 key trends
Competitive landscape
Retailing developments
What next for consumer health?
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
The following categories and subcategories are included:
Analgesics
-
-
- Adult Acetaminophen
- Adult Aspirin
- Adult Combination Products - Analgesics
- Adult Diclofenac
- Adult Dipyrone
- Adult Ibuprofen
- Adult Ketoprofen
- Adult Naproxen
- Adult OTC Triptans
-
- Paediatric Acetaminophen
- Paediatric Aspirin
- Paediatric Combination Products - Analgesics
- Paediatric Dipyrone
- Paediatric Ibuprofen
- Paediatric Naproxen
-
- Acetaminophen
- Aspirin
- Combination Products - Analgesics
- Diclofenac
- Dipyrone
- Ibuprofen
- Ketoprofen
- Naproxen
- OTC Triptans
-
- Topical Analgesics/Anaesthetic
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Analgesics research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!